ARCHIVES

DCT Board Oks Recompetition Of Master Agreement For BRM Trials

This article is from The Cancer Letter archive.

Vol. 09 No. 05 | February 4, 1983

Download PDF Visit The Full Archive

Related Articles

Medicare Should Pay Routine Care For Patients in Trials: IOM.

January 7, 2000

Seattle Times, The Hutch Duel Over Five-Part Series.

March 23, 2001

FDA Clears Avastin-Interferon Combination In Renal Cancer; Interferon Role Undefined.

August 7, 2009

NCI director apologizes to cancer centers for inaction on working group report.

October 31, 2003

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

December 9, 2005

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013